![CeGaT_Logo_RGB_o-S_Color-[SCREEN]](https://www.precisionmedicineforum.com/conference/wp-content/uploads/2022/12/CeGaT_Logo_RGB_o-S_Color-SCREEN.jpg){kind=logo}
Immuno-Oncology Forum
26-27 June 2023 | Stockholm
Following the success of the Nordic Precision Medicine Forum we are thrilled to announce the inaugural Nordic Oncology Forum, a multi topic meeting dedicated to advancing the diagnosis, prognosis and treatment of cancer in and across the Nordics.
In recent years immunotherapies have emerged as a new standard of care in the treatment of a wide variety of malignancies. With numerous therapeutic modalities and mechanistic approaches being developed from immune modulation to multi-specific antibodies, to cancer vaccines and cell-based approaches, all empowering the immune system to prevent, control, and eliminate cancer. The Immuno-Oncology Forum will address such promising immunotherapies, how they are performing in the clinic and how they can be combined with precision medicine approaches to further increase the standard of care.
Agenda
The agenda for 2023 is currently in production and will be released soon. To be informed when it is available, please contact us.
Speaking
From keynotes to panel discussions, industry satellites to posters, speaking at our Forum puts you in front of the right people. Speaking opportunities are limited so if you feel you have something you can bring to the table please contact us.
Sponsor
The foundation, and we believe the success of our events, lies in the preparation. Extensive research, engagement with industry leaders and targeted marketing campaigns ensure that we produce timely, relevant programmes, and bring the right people together.
Our Speakers
Speakers for Precision Oncology Forum comprises C-Level multidisciplinary group of experts drawn from healthcare, industry, patient groups, research, payers and Government. The programme is currently in production. We will be releasing the confirmed speakers soon and a full agenda in early 2023.
Contact Joel Hornby
Khalid Shah, MS, PhD.
Vice Chairman of Research, Department of Neurosurgery, Brigham and Women’s Hospital
Prof. Anders Ståhlberg
Professor in Clinical Genomics, is working as principal investigator at Sahlgrenska Center for Cancer Research
Ivan Diaz-Padilla, MD, PhD
Vice-President, Oncology Clinical Development, Global Head, Immuno-Oncology, GSK
Hans van der Vliet, MD PhD
Scientific founder and Chief Scientific Officer of LAVA Therapeutics
Alexander M.M. Eggermont, MD, PhD
Prof Immunotherapy University Medical Center Utrecht, Comprehensive Cancer Center Munich
Michael Uhlin, PhD
Division Head and Professor in Clinical Immunology at Karolinska Institutet.
Mathias Uhlen
Founding Director of the Science for Life Laboratory (SciLifeLab), a Swedish national center for molecular bioscience.
Gal Cafri, PhD
Gal Cafri (Ph.D.), Immunotherapy and genetic engineering group leader, Sheba Medical Center
Prof Hans Gelderblom
Heads department of medical oncology at Leiden University Medical Center, Netherlands
Prof Iwona Lugowska
Prof. Iwona Lugowska, MD PhD Head of the Early Phase Clinical Trials Unit, NIO-PIB, Poland
Åslaug Helland
Research Director at the OECI-accredited Oslo Comprehensive Cancer Centre.
Paul A. Frohna, MD, PhD, PharmD
Chief Medical & Scientific Officer, ImCheck Therapeutics
Anna Pasetto, PhD
Director of the Center for Advanced Cell Therapy (ACT), University of Oslo
Luca Gattinoni
Director, Division of Functional Immune Cell Modulation, Leibniz Institute of Immunotherapy, Regensburg, Germany
Prof Dr Ed Schuuring, PhD
Senior clinical scientist in molecular pathology, University Medical Center Groningen
Angus Dalgleish
Foundation Professor at St George’s University of London and Principal of the ICVI.
Merel Hennink
Merel started the foundation Stichting Merels Wereld to raise awareness about ROS1.
Jon A Kyte MD PhD
Head, Department of Clinical Cancer Research, Research Group Leader, Department of Cancer Immunology, Oslo University Hospital
Lisa Vervueren, MD
Pharmaceutical expert, NIHDI (Belgium), HTA Taskforce Beneluxa Initiative.
